BiotechTube

Linaclotide + Placebo

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome Characterized by Constipation

Conditions

Irritable Bowel Syndrome Characterized by Constipation

Trial Timeline

Dec 21, 2016 → Oct 31, 2018

NCT ID
NCT02837783

About Linaclotide + Placebo

Linaclotide + Placebo is a approved stage product being developed by Ironwood Pharmaceuticals for Irritable Bowel Syndrome Characterized by Constipation. The current trial status is terminated. This product is registered under clinical trial identifier NCT02837783. Target conditions include Irritable Bowel Syndrome Characterized by Constipation.

What happened to similar drugs?

6 of 20 similar drugs in Irritable Bowel Syndrome Characterized by Constipation were approved

Approved (6) Terminated (0) Active (14)
✅Ramosetron + PlaceboAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅Bacillus clausii + MetronidazoleSanofiApproved
✅Iberogast® and Iberogast® NBayerApproved
✅LinaclotideIronwood PharmaceuticalsApproved
🔄YM060 + PlaceboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT04110145Phase 2Completed
NCT03573908Phase 3Completed
NCT02837783ApprovedTerminated

Competing Products

20 competing products in Irritable Bowel Syndrome Characterized by Constipation

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
35
YM060 + PlaceboAstellas PharmaPhase 3
40
Ramosetron + PlaceboAstellas PharmaApproved
43
Ramosetron + PlaceboAstellas PharmaApproved
43
YM060Astellas PharmaPhase 3
40
YM060 + placeboAstellas PharmaPhase 2
35
YM060Astellas PharmaPhase 3
40
linaclotide + PlaceboAstellas PharmaPhase 3
40
RamosetronAstellas PharmaPre-clinical
26
YM060Astellas PharmaPhase 2
35
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
27
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
35
duloxetineEli LillyApproved
43
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
40
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
47
Eluxadoline + PlaceboAbbViePhase 2
42
Placebo + LinaclotideAstraZenecaPhase 3
40
TegaserodNovartisPre-clinical
26
DNK333NovartisPhase 2
35
SMS995 + PlaceboNovartisPhase 1
29